Alkermes
ISIN IE00B56GVS15
|WKN A1JKVH
Overview
Description
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Ireland
Financials
Key metrics
| Market capitalisation, EUR | 3,925.19 m |
| EPS, EUR | 2.02 |
| P/B ratio | 2.99 |
| P/E ratio | 12.45 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 1,439.99 m |
| Net income, EUR | 344.03 m |
| Profit margin | 23.89% |
What ETF is Alkermes in?
There are 34 ETFs which contain Alkermes. All of these ETFs are listed in the table below. The ETF with the largest weighting of Alkermes is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
